Figure 3
From: RFC2: a prognosis biomarker correlated with the immune signature in diffuse lower-grade gliomas
The correlation between RFC2 expression and clinicopathological characteristics in primary LGG patients (TCGA cohort, n = 537). (A–G) The correlations of RFC2 expression with LGG clinicopathological features, including age (A), gender (B), WHO grade (C), pathological classification (D), IDH1 mutation status (E), radiation therapy history (F), and seizure history (G). (H) Heatmap showing the association between RFC2 expression and clinicopathological characteristics in LGG patients. (*P < 0.05, **P < 0.01, ***P < 0.001).
